Milestone Medical (MIST)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Ophthalmology IOPsrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-05. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 49/100 (MEDIUM), 38.7 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 130.54% of float, squeeze risk: HIGH
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Milestone Pharmaceuticals Enrolls First Canadian Study Participant in ReVeRA-301 Phase 3 Pivotal Trial Evaluating Etripamil Nasal Spray for AFib-RVR
- Milestone Pharmaceuticals Announces NMPA Approval of Etripamil Nasal Spray for PSVT in China, Marking First Regulatory Approval of Etripamil Outside of the United States
- Milestone Pharmaceuticals to Present at Upcoming Investor Conferences
- Milestone Pharmaceuticals shares rise as first patient enters Phase 3 AFib trial
- Milestone Pharmaceuticals Initiates Pivotal Phase 3 Trial of Etripamil Nasal Spray for Self-Administered Treatment of Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR)
- Milestone Pharmaceuticals Q2 Earnings Call Highlights
- Milestone Pharmaceuticals (MIST) Reports Q2 Loss, Lags Revenue Estimates
- Milestone Pharmaceuticals shares tumble after Q2 earnings miss
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Milestone Medical.
Full MIST Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.